Citalopram: an Interaction Study with Clomipramine in a Patient Heterozygous for CYP2D6 Genotype

A pharmacokinetic interaction between the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant, clomipramine, was noted in a patient treated for major depression and obsessive-compulsive disorder. After the addition of citalopram, a desmethylclomipramine plasma level increase and an 8-hydroacy-desmethylclomipramine plasma level decrease were observed. The CYP2D6 phenotype, determined when the patient received the antidepressant comedication, characterized a poor metabolizer status (dextromethorphan metabolic ratio > 0.3), despite a heterozygous genotype containing a wild-type allele with extensive metabolic capacity and a mutant non-functional allele (CYP2D6*1A/CYP2D6*4A). This case seems to be one of the first descriptions of the clinical relevance of a CYP2D6 heterozygous genotype in a patient treated with antidepressant.

References

• 1 Nielsen K-K, Brosen K. High performance liquid chromatography of clomipramine and metabolites in human plasma and urine.  Ther. Drug Monit.. 1993;  15 122-128
• 2 Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, Lo Guidice L. et al . An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.  Pharmacogenetics. 1995;  5 373-384
• 3 Baumann P, Jonzier-Perey M. GC and GC-MS procedure for simultaneous phenotyping with dextromethorphan aud mephenytoin.  Clin. Chim. Acta. 1988;  171 211-222
• 4 Baumann P, Meyer J-W, Amey M, Baettig D, Bryois D, Jonzier-Perey M. et al . Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline.  Ther. Drug Monit.. 1992;  14 1-8
• 5 Barr L-C, Goodman W-K, Anand A, McDougle C-J, Price L-H. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive compulsive disorder.  Am. J. Psychiatry. 1997;  154 1293-1295
• 6 Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.  Clin. Pharmacokinet.. 1996;  31 444-469
• 7 Preskorn S H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.  Clin. Pharmacokinet.. 1997;  32(s) 1-21
• 8 Crewe H-K, Lennard M-S, Tucker G-T, Woods F-R, Haddock R-E. The effect of selective serotonin reuptake inhibitors on cytochrome P450 (CYP2D6) activity in human liver microsomes.  Br. J. Clin. Pharmacol.. 1992;  34 262-265
• 9 Ereshefsky L, Riesenman C, Lam Y WF. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.  Clin. Pharmacokinet.. 1995;  29(s) 10-19
• 10 Rochat B, Amey M, Gillet M, Meyer U-A, Baumann P. Identification of three cytochromes P450 involved in N-demethylation of citalopram enantiomers in human liver microsomes.  Pharmacogenetics. 1997;  7 1-10
• 11 Sindrup S-H, Brosen K, Hansen M-G, Aaes-Jorgensen T, Overo K-F, Gram L-F. Pharmacokinetics of citalopram in relation to the sparteine and mephenytoin oxidation polymorphisms.  Ther. Drug Monit.. 1993;  15 11-17
• 12 Valoti M, Frosini M, Palmi M, De Matteis F, Sgaragli G. N-dealkylation of chlorimipramine and chlorpromazine by rat liver microsomal cytochrome P450 isozymes.  J. Pharm. Pharmacol.. 1998;  50 1005-1011
• 13 Nielsen K-K, Brosen K, Hansen M-G-J, Gram L-F. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.  Clin. Pharmacol. Ther.. 1994;  55 518-527
• 14 Baettig D, Bondolfi G, Montaldi S, Amey M, Baumann P. Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study.  Eur. J. Clin. Pharmacol.. 1993;  44 403-405
• 15 Leinonen E, Lepola U, Koponen H, Kinnunen I. The effect of age and concomittant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method.  Ther. Drug Monit.. 1996;  18 111-117
• 16 Jeppesen U, Gram L-F, Vistisen K, Loft S, Poulsen H-E, Brosen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.  Eur. J. Clin. Pharmacol.. 1996;  51 73-78
• 17 Lepola U, Leinonen E, Koponen H. Increased serum drug concentrations in concomitant treatment with citalopram, clomipramine and alprazolam.  Eur. Psychiatry. 1994;  9 312-314
• 18 Gram L-F, Hansen M-G-J, Sindrup S-H, Brosen K, Poulsen J-H, Aaes-Jorgensen T. et al . Citalopram: interaction studies with levomepromazine, imipramine and lithium.  Ther. Drug Monit.. 1993;  15 18-24
• 19 Morgan E T, Sewer M B, Iber H, Gonzalez F J, Lee Y H, Tukey R H, Okino S, Vu T, Chen Y H, Sidhu J S, Omiecinski C J, Anthony Y H. Lu commemorative issue. Physiological and pathophysiological regulation of cytochrome P450.  Drug Met. Disp.. 1998;  26 -1240
• 20 Koytchef R, Alken R-G, Vlahov V, Kirrov V, Kaneva R, Thyroff-Friesinger U. et al . Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metaprolol.  Eur. J. Clin. Pharmacol.. 1998;  54 469-474
• 21 Griese E-U, Zanger U-M, Brudermanns U, Gaedigk A, Mikus G, Morike K. et al . Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a german population.  Pharmacogenetics. 1998;  8 15-26